A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

  • STATUS
    Recruiting
  • End date
    Oct 23, 2024
  • participants needed
    77
  • sponsor
    Celgene
Updated on 30 November 2021
ct scan
cancer
hodgkin's disease
measurable disease
positron emission tomography
nivolumab
follicular lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
large b-cell lymphoma
ibrutinib
high grade b-cell lymphoma
lactate dehydrogenase
indolent non-hodgkin lymphoma

Summary

This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug combinations with JCAR017, as separate arms, over the life of the protocol, using the same objectives. Each combination will be evaluated separately (ie, the intention is not to compare between combinations) for the purposes of the objectives, trial design, and statistical analysis. The following combinations will be tested:

Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122 (avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents have been selected.

The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.

Description

During Phase 1, different arms may be opened to test JCAR017 in combination with combination agent(s) in adult subjects with R/R aggressive B-cell NHL. Within each arm, different doses and schedules of JCAR017 and the combination agent(s) may be tested in several cohorts and subcohorts per arm. During Phase 2 of the study, the expansion of any dose level and schedule for any arm that has been shown to be safe may occur.

Arm A will test JCAR017 in combination with Durvalumab Arm B will test JCAR017 in combination with CC-122 Arm C will test JCAR017 in combination with CC-220 (iberdomide ) Arm D will test JCAR017 in combination with ibrutinib. Arm E will test JCAR017 in combination with relatlimab and/or nivolumab Arm F will test JCAR017 in combination with CC-99282 All subjects from Phase 1 and Phase 2 will be followed for 24 months following JCAR017 infusion. Post-study follow-up for survival, relapse, long-term toxicity (including new malignancies), and viral vector safety will continue under a separate long-term follow-up (LTFU) protocol for up to 15 years after the JCAR017 dose as per health authority regulatory guidelines.

Details
Condition Follicular Lymphoma, non-hodgkin's lymphoma (nhl), Diffuse Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's Lymphoma
Treatment Ibrutinib, Nivolumab, durvalumab, Relatlimab, CC-122, CC-220, JCAR017, CC-99282
Clinical Study IdentifierNCT03310619
SponsorCelgene
Last Modified on30 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject is 18 years of age at the time of signing the informed consent form ()
Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
Subject is willing and able to adhere to the study visit schedule and other protocol requirements
Subject must have histologically confirmed at last relapse aggressive B-cell NHL according to "The 2016 revision of the WHO classification of lymphoid neoplasms" defined as
Diffuse large B-cell lymphoma (DLBCL) Not otherwise specified (NOS) including transformed indolent Non-Hodgkin lymphoma (NHL)
Follicular lymphoma Grade 3B
T cell/histiocyte-rich large B-cell lymphoma
Epstein-Barr virus (EBV) positive DLBCL, NOS
Primary mediastinal (thymic) large B-cell lymphoma
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)
Subjects disease must have relapsed or be refractory to at least 2 prior lines of therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline
Subject must have
Positron emission tomography (PET)-positive (Deauville score 4 or 5) and computed tomography (CT) measurable disease as per Lugano Classification
Sum of product of perpendicular diameters (SPD) of up to 6 index lesions 25 cm2 by CT scan (not applicable to Arm A or B or subjects with Richter's transformation)
Eastern Cooperative Oncology Group (ECOG) performance status 1 at screening
Adequate organ function
Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals
Participants must agree to use effective contraception

Exclusion Criteria

Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study based on investigators judgment
Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study based on investigators judgment
Subject has any condition that confounds the ability to interpret data from the study based on investigators judgment
Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the subject has been free of the disease for 2 years with the exception of the following non-invasive malignancies
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Carcinoma in situ of the cervix
Carcinoma in situ of the breast
Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative
Other completely resected stage 1 solid tumor with low risk for recurrence
Prior treatment with any prior gene therap y product
Prior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowed
Allogeneic HSCT within 90 days of leukapheresis
Prior treatment with the combination agent from the assigned arm
Anti PD-1 or PD-L1 (Arm A and E)
CC-122 (Arm B)
CC-220 (Arm C)
Prior treatment with ibrutinib is not exclusionary for subjects on any study arm
Anti LAG-3 targeted agent (Arm E)
Presence of acute or chronic graft-versus-host disease (GVHD)
CC-99282 (Arm F)
History of or active hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infection
Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusion
History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
Any history of myocarditis (Arm E); history of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease (all arms)
Subjects with active CNS or cerebrospinal fluid (CSF) involvement by malignancy
Pregnant or nursing (lactating) women
Subjects with active auto immune disorders/processes or active neurological or inflammatory disorders
For subjects to receive oral combination therapy (Arms B, C, D or F): History of a gastrointestinal (GI) condition or procedure that in the opinion of the investigator may affect oral drug absorption
Progressive tumor invasion of venous or arterial vessels
Deep venous thrombosis (DVT)/pulmonary embolism (PE) not managed on a stable regimen of anticoagulation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note